Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 16, Issue 9, Pages 759-768Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425255.2020.1789591
Keywords
Endometriosis; hormonal therapy; gonadotropin-releasing hormone analogs; add-back therapy; norethisterone acetate; combined oral contraceptives; bone mineral density; vasomotor symptoms
Ask authors/readers for more resources
Introduction The second-line treatment of endometriosis-related pain symptoms includes injectable depot formulations of gonadotropin-releasing hormone analogs (GnRH-as). These drugs improve the symptomatology by inducing a hypoestrogenic status and a consequent regression of endometriotic implants. However, GnRH-a may cause a not negligible rate of adverse events, in particular vasomotor symptoms and bone mineral density loss, that may limit patients' adherence and safety on long-term treatment. Several strategies have been suggested to improve the compliance to treatment. Areas covered This narrative review aims to give an overview of the safety and tolerability of GnRH-a therapy and to present the different options of steroidal and non-steroidal add-back therapies in order to reduce the hypoestrogenic side effects. Expert opinion Side effects of long term GnRH-a treatment are particularly relevant. Although it has been known the efficacy of GnRH-as for treating endometriosis-associated pain, the best schedules of therapy in terms of duration and dosages are still to be defined. The ideal treatment schedule of GnRH-a is still a matter of debate as to the optimal add-back combination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available